Page last updated: 2024-09-04
pralnacasan and nimodipine
pralnacasan has been researched along with nimodipine in 1 studies
Compound Research Comparison
Studies (pralnacasan) | Trials (pralnacasan) | Recent Studies (post-2010) (pralnacasan) | Studies (nimodipine) | Trials (nimodipine) | Recent Studies (post-2010) (nimodipine) |
---|---|---|---|---|---|
19 | 0 | 7 | 2,936 | 317 | 597 |
Protein Interaction Comparison
Protein | Taxonomy | pralnacasan (IC50) | nimodipine (IC50) |
---|---|---|---|
Voltage-dependent L-type calcium channel subunit alpha-1C | Cavia porcellus (domestic guinea pig) | 0.11 | |
Cytochrome P450 2C9 | Homo sapiens (human) | 2.19 | |
Cannabinoid receptor 1 | Homo sapiens (human) | 1.736 | |
Cytochrome P450 2C19 | Homo sapiens (human) | 4 | |
Cytochrome P450 2J2 | Homo sapiens (human) | 3.38 | |
Voltage-dependent calcium channel subunit alpha-2/delta-1 | Homo sapiens (human) | 0.0298 | |
Voltage-dependent L-type calcium channel subunit beta-2 | Homo sapiens (human) | 0.0298 | |
cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | 7.15 | |
Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 0.0699 | |
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Homo sapiens (human) | 1.243 | |
Bile acid receptor | Homo sapiens (human) | 8.96 |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Reviews
1 review(s) available for pralnacasan and nimodipine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |